Tempest Therapeutics (TPST) News Today $7.76 -0.29 (-3.60%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$7.86 +0.10 (+1.22%) As of 04/25/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Cash-strapped Bay Area biotech company lays off all but 5 employeesApril 24 at 6:33 PM | msn.comTempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-1495April 23, 2025 | nasdaq.comTempest Therapeutics Receives FDA Orphan Drug Designation for TPST-1495 to Treat Familial Adenomatous PolyposisApril 23, 2025 | nasdaq.comTempest Therapeutics stock rises on FDA Orphan Drug DesignationApril 21, 2025 | in.investing.comTempest Therapeutics announces FDA granted ODD to TPST-1495April 21, 2025 | markets.businessinsider.comTempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAPApril 21, 2025 | globenewswire.comScotiabank Reiterates Sector Perform Rating for Tempest Therapeutics (NASDAQ:TPST)Scotiabank reiterated a "sector perform" rating and set a $9.00 price target (up from $7.00) on shares of Tempest Therapeutics in a research report on Thursday.April 12, 2025 | marketbeat.comHC Wainwright Reiterates "Neutral" Rating for Tempest Therapeutics (NASDAQ:TPST)HC Wainwright reiterated a "neutral" rating and issued a $16.00 price target on shares of Tempest Therapeutics in a research note on Thursday.April 12, 2025 | marketbeat.comScotiabank Downgrades Tempest Therapeutics (TPST)April 11, 2025 | msn.comTempest Therapeutics downgraded to Sector Perform from Outperform at ScotiabankApril 10, 2025 | markets.businessinsider.comTempest Therapeutics downgraded to Neutral from Buy at H.C. WainwrightApril 10, 2025 | markets.businessinsider.comTempest hits funding block for Phase III liver cancer drug-in-waitingApril 10, 2025 | finance.yahoo.comTempest Therapeutics downgraded at Scotiabank as amezalpat finds no suitorsApril 10, 2025 | markets.businessinsider.comTempest Therapeutics to explore strategic alternativesApril 10, 2025 | markets.businessinsider.comTempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible MergerApril 10, 2025 | msn.comTempest Therapeutics Seeks Partner as It Explores Strategic AlternativesApril 9, 2025 | marketwatch.comTempest Therapeutics Terminates Loan Agreement with OxfordApril 9, 2025 | tipranks.comTempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder ValueApril 9, 2025 | globenewswire.comTempest Therpeutics trading halted, news pendingApril 9, 2025 | markets.businessinsider.comTempest Therapeutics price target lowered to $7 from $13 at ScotiabankMarch 28, 2025 | markets.businessinsider.comTempest Therapeutics price target lowered to $16 from $47 at H.C. WainwrightMarch 28, 2025 | markets.businessinsider.comTempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business UpdateMarch 28, 2025 | finanznachrichten.deWilliam Blair Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)March 28, 2025 | markets.businessinsider.comTempest Reports Year End 2024 Financial Results and Provides Business UpdateMarch 27, 2025 | globenewswire.comTempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comTempest Therapeutics received ‘Study May Proceed’ letter from FDA on TPST-1495March 13, 2025 | markets.businessinsider.comFDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)March 13, 2025 | globenewswire.comTempest Therapeutics granted FTD from FDA for amezalpatFebruary 11, 2025 | markets.businessinsider.comTempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular CarcinomaFebruary 10, 2025 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comFDA grants ODD to Tempest’s hepatocellular carcinoma treatmentJanuary 7, 2025 | finance.yahoo.comTempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)January 6, 2025 | globenewswire.comTempest Therapeutics Inc TPSTDecember 15, 2024 | morningstar.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comFavourable Signals For Tempest Therapeutics: Numerous Insiders Acquired StockNovember 28, 2024 | finance.yahoo.comTempest to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | globenewswire.comTempest Therapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comTempest Therapeutics price target lowered to $5 from $8 at Piper SandlerNovember 13, 2024 | markets.businessinsider.comTempest Therapeutics: Promising Advancements and Strategic Partnerships Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comTempest Therapeutics: Tempest Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finanznachrichten.deTempest receives FDA study may proceed for Phase 3 trial of amezalpatNovember 13, 2024 | markets.businessinsider.comTempest Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finance.yahoo.comTempest Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comTempest Therpeutics options imply 22.5% move in share price post-earningsNovember 9, 2024 | markets.businessinsider.comTraders Digest Consumer Inflation Measure as US Equity Futures Drop Pre-BellOctober 12, 2024 | msn.comScotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)October 11, 2024 | markets.businessinsider.comTempest Agrees To Extend Limited Duration Stockholder Rights PlanOctober 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tempest Therapeutics Amid Positive Developments and Strategic Roche CollaborationOctober 10, 2024 | markets.businessinsider.comWhy Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?October 10, 2024 | finance.yahoo.comPerimeter Solutions (NYSE:PRM) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.com Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address TPST Media Mentions By Week TPST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TPST News Sentiment▼0.170.86▲Average Medical News Sentiment TPST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TPST Articles This Week▼71▲TPST Articles Average Week Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CCCC News ZNTL News ALEC News TNXP News SLN News COYA News BHST News IMUX News ELUT News ZURA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TPST) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
